TPST - Tempest Secures Exclusive Option to License Clinical -Stage CD7-Targeted Lentiviral In Vivo CAR-T Platform
TPST - Tempest Secures Exclusive Option to License Clinical -Stage CD7-Targeted Lentiviral In Vivo CAR-T Platform
Find public news by keyword, exact ticker, category and date.
Open a ticker page for its news coverage. The news search below stays a text search.
1 result loaded, newest first. End of these results.
TPST - Tempest Secures Exclusive Option to License Clinical -Stage CD7-Targeted Lentiviral In Vivo CAR-T Platform